Catalyst Pharmaceuticals Inc (CPRX)
17.59
+0.22
(+1.27%)
USD |
NASDAQ |
Jul 26, 16:00
17.41
-0.18
(-1.02%)
After-Hours: 20:00
Catalyst Pharmaceuticals PS Ratio: 4.890 for July 26, 2024
PS Ratio Chart
Historical PS Ratio Data
| Date | Value |
|---|---|
| July 25, 2024 | 4.829 |
| July 24, 2024 | 4.868 |
| July 23, 2024 | 4.882 |
| July 22, 2024 | 4.726 |
| July 19, 2024 | 4.709 |
| July 18, 2024 | 4.648 |
| July 17, 2024 | 4.698 |
| July 16, 2024 | 4.723 |
| July 15, 2024 | 4.656 |
| July 12, 2024 | 4.609 |
| July 11, 2024 | 4.534 |
| July 10, 2024 | 4.298 |
| July 09, 2024 | 4.339 |
| July 08, 2024 | 4.295 |
| July 05, 2024 | 4.223 |
| July 03, 2024 | 4.256 |
| July 02, 2024 | 4.392 |
| July 01, 2024 | 4.384 |
| June 28, 2024 | 4.306 |
| June 27, 2024 | 4.181 |
| June 26, 2024 | 4.192 |
| June 25, 2024 | 4.212 |
| June 24, 2024 | 4.278 |
| June 21, 2024 | 4.334 |
| June 20, 2024 | 4.220 |
| Date | Value |
|---|---|
| June 18, 2024 | 4.162 |
| June 17, 2024 | 4.170 |
| June 14, 2024 | 4.187 |
| June 13, 2024 | 4.262 |
| June 12, 2024 | 4.295 |
| June 11, 2024 | 4.326 |
| June 10, 2024 | 4.345 |
| June 07, 2024 | 4.342 |
| June 06, 2024 | 4.381 |
| June 05, 2024 | 4.534 |
| June 04, 2024 | 4.459 |
| June 03, 2024 | 4.498 |
| May 31, 2024 | 4.495 |
| May 30, 2024 | 4.478 |
| May 29, 2024 | 4.414 |
| May 28, 2024 | 4.606 |
| May 24, 2024 | 4.412 |
| May 23, 2024 | 4.426 |
| May 22, 2024 | 4.487 |
| May 21, 2024 | 4.595 |
| May 20, 2024 | 4.704 |
| May 17, 2024 | 4.584 |
| May 16, 2024 | 4.559 |
| May 15, 2024 | 4.631 |
| May 14, 2024 | 4.584 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
2.678
Minimum
Sep 30 2020
11.16
Maximum
Dec 21 2022
5.214
Average
4.706
Median
Jul 19 2021
PS Ratio Benchmarks
| Vertex Pharmaceuticals Inc | 12.68 |
| Sarepta Therapeutics Inc | 9.781 |
| PTC Therapeutics Inc | 2.774 |
| Regenxbio Inc | 7.336 |
| Edgewise Therapeutics Inc | -- |
PS Ratio Related Metrics
| PE Ratio | 32.57 |
| Price to Book Value | 3.701 |
| Price to Free Cash Flow | 24.65 |
| Price | 17.59 |
| Earnings Yield | 3.07% |
| Market Cap | 2.078B |
| Operating PE Ratio | 25.68 |
| Normalized PE Ratio | 32.57 |